Myotonic Dystrophy – Vascular and Cognition

Learn more about:
Related Clinical Trial
DMCRN-02-001: Assessing Pediatric Endpoints in DM1 Myotonic Dystrophy Type 1 and Resistance Exercise Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients Biomarker Development for Muscular Dystrophies Extracellular RNA Biomarkers of Myotonic Dystrophy Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1 Myotonic Dystrophy – Vascular and Cognition Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Open Label Study in Adolescents and Children With Myotonic Disorders European Home Mechanical Ventilation Registry Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 Efficacy and Safety of DHEA for Myotonic Dystrophy Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 DM-IMT – Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 Venous Thromboembolism in DM1 Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study) Children’s Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Observational Prolonged Trial in Myotonic Dystrophy Type 1 Venous Thromboembolism in Myotonic Dystrophy Type 1 Myotonic Dystrophy Type 1 Aerobic Exercise Study Multicenter Observational Study of Myotonic Dystrophy Type 1 DM1 Heart Registry – DM1 Respiratory Registry

Brief Title

Myotonic Dystrophy - Vascular and Cognition

Official Title

Links Between Diabetes and Cognitive Impairment in Myotonic Dystrophy Type 1 : a Non-conventional MRI Study

Brief Summary

      The cognitive disorders of adult forms of myotonic dystrophies type 1 are heterogeneous
      (impairment of executive functions, visio construction and theory of the mind, which can
      progress to the stage of dementia). Nevertheless, patients have very different degrees of
      cognitive impairment. Expansion of CTG triplets disrupts the alternative splicing of mRNAs of
      various proteins, including the insulin receptor and Tau protein. Type 2 diabetes, associated
      with peripheral insulin resistance, is therefore common in this pathology.

      Type 2 diabetes,could to explain the cognitive impairment of patients, through the
      accelerated development of brain lesions (especially tauopathy and cerebral atrophy).
    



Study Type

Observational


Primary Outcome

Atrophy difference based on two cerebral MRI volumetries

Secondary Outcome

 changes in scores at 4-year neuropsychological assessment of inclusion

Condition

Myotonic Dystrophy 1

Intervention

MRI

Study Arms / Comparison Groups

 Group 1: MD type 1 normal
Description:  patients with type 1 myotonic dystrophy with normal carbohydrate tolerance

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Radiation

Estimated Enrollment

150

Start Date

October 14, 2021

Completion Date

January 2029

Primary Completion Date

January 2029

Eligibility Criteria

        Inclusion Criteria:

          -  Molecularly proven type 1 myotonic dystrophy

          -  Voluntary, having given informed consent

          -  Socially insured patient

          -  Patient willing to comply with all study procedures and duration (3 hours + MRI 35
             minutes)

          -  Patient insured under the French social security system

          -  Signed consent form

        Exclusion Criteria:

          -  Neurological history other than neuropathy: epilepsy, stroke, dementia

          -  Pregnancy or breastfeeding or woman of childbearing age without effective
             contraception (a pregnancy test will be done)

          -  Contra indication to MRI

          -  Person under guardianship or curators

          -  Persons of full age deprived of their liberties by a judicial or administrative
             decision

          -  Major comorbidity considered as a contraindication by the investigator (cancer,
             unstable angina, etc.).
      

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Céline TARD, MD, 0320445962, [email protected]

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT04656210

Organization ID

2018_31

Secondary IDs

2019-A00086-51

Responsible Party

Sponsor

Study Sponsor

University Hospital, Lille


Study Sponsor

Céline TARD, MD, Principal Investigator, University Hospital, Lille


Verification Date

February 2022